NTRK1 and non-small cell lung carcinoma: Repotrectinib (TPX-0005) is a next-generation receptor tyrosine kinase (ROS1), pan-TRK, and anaplastic lymphoma kinase (ALK) TKI inhibitor, created to overcome refractory SFMs which often occur in patients with ROS1/NTRK/ALK-rearranged malignancies, such as NSCLC.